This company listing is no longer active
ChemoCentryx Balance Sheet Health
Financial Health criteria checks 4/6
Key information
10.5%
Debt to equity ratio
US$24.92m
Debt
Interest coverage ratio | n/a |
Cash | US$328.62m |
Equity | US$236.53m |
Total liabilities | US$182.86m |
Total assets | US$419.39m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 2CX's short term assets ($345.2M) exceed its short term liabilities ($76.1M).
Long Term Liabilities: 2CX's short term assets ($345.2M) exceed its long term liabilities ($106.8M).
Debt to Equity History and Analysis
Debt Level: 2CX has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 2CX's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2CX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 2CX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.